Cerevel Therapeutics Holdings(US:CERE) Prnewswireยท2025-05-21 09:25Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Cerevel - The lawsuit alleges that during the class period, Cerevel made false and misleading statements related to its secondary stock offering on October 16, 2023, and its proxy statement on January 18, 2024 [5]. - It is claimed that Bain Capital and Pfizer orchestrated the secondary stock offering to allow Bain to increase its stake at a discounted price before AbbVie Inc.'s acquisition announcement, which was made 51 days later at $45 per share, nearly double the offering price [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].